AI Article Synopsis
- A study of 30,311 infants found that maternal vaccination against COVID-19 significantly reduced infection rates during the Delta variant period, with effectiveness at 84% in the first 2 months of life.
- In contrast, during the Omicron variant period, the effectiveness of maternal vaccination dropped significantly, showing only 21% effectiveness in the first 2 months.
- Infants born to vaccinated mothers had a much lower rate of COVID-19 hospitalization (21/100,000 person-years) compared to those born to unvaccinated mothers (100/100,000 person-years), indicating maternal vaccination provided some protective benefits, albeit decreasing over time and with variant changes.
Article Abstract
We examined the effectiveness of maternal vaccination against SARS-CoV-2 infection in 30,311 infants born at Kaiser Permanente Northern California from December 15, 2020, to May 31, 2022. Using Cox regression, the effectiveness of ≥2 doses of COVID-19 vaccine received during pregnancy was 84% (95% confidence interval [CI]: 66, 93), 62% (CI: 39, 77) and 56% (CI: 34,71) during months 0-2, 0-4 and 0- 6 of a child's life, respectively, in the Delta variant period. In the Omicron variant period, the effectiveness of maternal vaccination in these three age intervals was 21% (CI: -21,48), 14% (CI: -9,32) and 13% (CI: -3,26), respectively. Over the entire study period, the incidence of hospitalization for COVID-19 was lower during the first 6 months of life among infants of vaccinated mothers compared with infants of unvaccinated mothers (21/100,000 person-years vs. 100/100,000 person-years). Maternal vaccination was protective, but protection was lower during Omicron than during Delta. Protection during both periods decreased as infants aged.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9974935 | PMC |
| http://dx.doi.org/10.1038/s41467-023-36547-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Meeting summary: Global vaccine and immunization research forum, 2023.
Vaccine
January 2025
Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, MSC 9825, Bethesda, MD 20892-9825, USA. Electronic address:
At the 2023 Global Vaccine and Immunization Research Forum (GVIRF), researchers from around the world gathered in the Republic of Korea to discuss advances and opportunities in vaccines and immunization. Many stakeholders are applying the lessons of Covid-19 to future emergencies, by advancing early-stage development of prototype vaccines to accelerate response to the next emerging infectious disease, and by building regional vaccine research, development, and manufacturing capacity to speed equitable access to vaccines in the next emergency. Recent vaccine licensures include: respiratory syncytial virus vaccines, both for the elderly and to protect infants through maternal immunization; a new dengue virus vaccine; and licensure of Covid-19 vaccines previously marketed under emergency use authorizations.
View Article and Find Full Text PDFDemographic, social and health system factors associated with maternal mortality in Pakistan: A nested case-control study.
PLoS One
January 2025
Ministry of National Health Services, Regulations and Coordination, Islamabad, Pakistan.
Background: Pakistan has experienced a significant reduction in maternal mortality with a decline of 33 percent between 2006 and 2019. However, the country still grapples with a high number (186 per 100,000 live births) of maternal deaths each year. This study aims to identify socio-demographic and health system related factors associated with maternal mortality.
View Article and Find Full Text PDFAwareness, Acceptability and Factors Influencing Malaria Vaccine Uptake Among Caregivers of Children Under 5 in South-Western Nigeria.
Child Care Health Dev
January 2025
Statistics Programme, Bowen University, Iwo, Osun State, Nigeria.
Background: Malaria remains a major cause of preventable deaths among children worldwide, despite the availability of several interventions for controlling and eliminating the disease. The WHO recommended the first malaria vaccine, RTS, S/AS01 in October 2021 to immunize children in sub-Saharan Africa. In this study, we set out to evaluate the knowledge, awareness and acceptability of the malaria vaccine among mothers of under 5 in south-west Nigeria before the vaccine's rollout in Nigeria.
View Article and Find Full Text PDFModulating cytokine microenvironment during T cell activation induces protective RSV-specific lung resident memory T cells in early life in mice.
Npj Viruses
December 2024
Department of Infectious Disease, Imperial College London, London, SW7 2AZ UK.
Maternal immunisation against respiratory viruses provides protection in early life, but as antibodies wane, there can be a gap in coverage. This immunity gap might be filled by inducing pathogen-specific lung tissue-resident T cells (TRM). However, the neonatal mouse lung has a different inflammatory environment to the adult lung which affects T cell recruitment.
View Article and Find Full Text PDFAssembling vaccine perspectives: Vaccination and moral self-talk in the journals of white US mothers during Covid-19.
SSM Qual Res Health
December 2024
Research Program on Global Health and Human Rights, Human Rights Institute, University of Connecticut, 405 Babbidge Road, U-1205, Storrs, CT, 06269, USA.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!